Vector Borne Diseases: Clinical Trials

419 trials for Vector Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

419 completed. 419 Phase 1, 79 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1419Completed 419
Phase 279Completed 79

Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases

Trials (filtered) newest first · largest first

All 419 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years
Midazolam (MDZ), GSK3772701 - Malaria, Falciparum
Phase 1CompletedGlaxoSmithKline202026-06-262026-09-30
First-in-Human Trial of Oral AN2-502998
AN2-502998, Placebo - Healthy Volunteers
Phase 1CompletedAN2 Therapeutics, Inc722025-08-042026-04-30
Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso
SUM-101 - Malaria,Falciparum
Phase 1CompletedEuropean Vaccine Initiative392025-08-012026-09-11
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9% - Malaria
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)222025-07-232026-08-17
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
Controlled Human Malaria Infection - Malaria (Plasmodium Falciparum)
Phase 1CompletedCentre de Recherche Médicale de Lambaréné202025-07-182026-09-11
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3 - Rift Valley Fever
Phase 1CompletedIDBiologics, Inc.402025-04-022026-11-10
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV - Healthy Volunteers
Phase 1CompletedGates Medical Research Institute1252025-03-282026-06-03
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
PfSPZ-LARC2 Vaccine, Normal Saline (Placebo) - Malaria Falciparum, Malaria Infection
Phase 1CompletedSanaria Inc.752025-03-042026-04-16
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease
Phase 1 / Phase 2CompletedSK Bioscience Co., Ltd.1612025-02-242026-09-11
Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever
N-pVAX1 - Crimean Congo Hemorrhagic Fever
Phase 1CompletedKarolinska Institutet152024-11-122026-03-23
Trial of an Inactivated Chikungunya Virus Vaccine
HydroVax-005 CHIKV, Placebo - Chikungunya Fever, Chikungunya Virus
Phase 1CompletedNajit Technologies, Inc.482024-11-042026-03-19
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184 - Zika Virus
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)272024-09-242026-03-09
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants
MMV371 LAI, Placebo for MMV371 - Malaria,Falciparum
Phase 1CompletedMedicines for Malaria Venture322024-08-272026-05-05
L9LS MAb in Malian Infants
L9LS, Placebo, R21/Matrix-MTM - Malaria
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)3272024-08-192026-10-01
Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
TB31F, Normal saline - Malaria,Falciparum
Phase 1 / Phase 2CompletedRadboud University Medical Center1672024-07-122026-01-22
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level - Yellow Fever, Rabies
Phase 1CompletedAstriVax Therapeutics1122024-06-162026-04-22
Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients
CPLE, Placebo - Dengue Fever
Phase 1 / Phase 2CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh1842024-06-012025-04-25
A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
BAY 44-4400 - Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness)
Phase 1CompletedBayer142024-05-072024-09-27
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
Plasmodium falciparum, MK-7602, Artemether/lumefantrine - Malaria
Phase 1CompletedMerck Sharp & Dohme LLC162024-04-182025-01-13
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
VLA1601, CpG 1018®, 3M-052-AF - Zika, Zika Virus Infection
Phase 1CompletedValneva Austria GmbH1502024-03-252026-03-09

Showing 20 of 419. Sign in to see all of them.

Narrower conditions

Malaria (222)  ·  Malaria, Falciparum (103)  ·  Dengue (55)  ·  Zika Virus Infection (21)  ·  Severe Dengue (16)  ·  Malaria, Vivax (15)  ·  Chikungunya Fever (9)  ·  Leishmaniasis (9)  ·  Parasitemia (8)  ·  Schistosomiasis (8)  ·  Virus Diseases (8)  ·  Chagas Disease (7)  ·  Leishmaniasis, Cutaneous (7)  ·  Infections (6)  ·  Parasitic Diseases (6)

Broader conditions

Infections (413)  ·  Mosquito-Borne Diseases (368)  ·  Parasitic Diseases (295)  ·  Protozoan Infections (287)  ·  RNA Virus Infections (109)  ·  Virus Diseases (107)  ·  Arbovirus Infections (105)  ·  Flaviviridae Infections (89)  ·  Flavivirus Infections (85)  ·  Hemorrhagic Fevers, Viral (66)  ·  Malaria (42)  ·  Euglenozoa Infections (27)  ·  Pathological Conditions, Signs and Symptoms (18)  ·  Skin Diseases (15)

Interventions

Saline Solution (17)  ·  Artemether, Lumefantrine Drug Combination (12)  ·  Aluminum Hydroxide (11)  ·  Primaquine (11)  ·  Chloroquine (9)  ·  Sodium Chloride (9)  ·  Vaccines (8)  ·  Matrix-M (7)  ·  Artesunate (6)  ·  Rabies Vaccines (6)  ·  Lumefantrine (5)  ·  ProMune (5)  ·  artefenomel (5)  ·  atovaquone, proguanil drug combination (5)  ·  fanasil, pyrimethamine drug combination (5)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (100)  ·  University of Oxford (51)  ·  Medicines for Malaria Venture (37)  ·  U.S. Army Medical Research and Development Command (34)  ·  Sanaria Inc. (20)  ·  GlaxoSmithKline (12)  ·  Drugs for Neglected Diseases (7)  ·  Access to Advanced Health Institute (AAHI) (6)  ·  Novartis Pharmaceuticals (6)  ·  Bayer (5)  ·  London School of Hygiene and Tropical Medicine (5)  ·  Radboud University Medical Center (5)  ·  European Vaccine Initiative (4)  ·  ModernaTX, Inc. (4)  ·  Pfizer (4)

Countries

United States (171)  ·  United Kingdom (55)  ·  Australia (23)  ·  Mali (21)  ·  Burkina Faso (12)  ·  Netherlands (12)  ·  Tanzania (10)  ·  Switzerland (9)  ·  France (7)  ·  Kenya (7)  ·  Thailand (7)  ·  Uganda (7)  ·  Belgium (6)  ·  Colombia (6)  ·  The Gambia (6)

Top investigators

Anna Durbin, MD (30)  ·  Patrick E Duffy, M.D. (7)  ·  Adrian V Hill, DPhill FRCP (5)  ·  Adrian VS Hill, D.Phil, FRCP (5)  ·  James McCarthy, Prof (5)  ·  Adrian V S Hill, MD (4)  ·  Kristen Pierce, MD (4)  ·  Ulrike Lorch, MD FRCA FFPM (4)  ·  Adrian VS Hill (3)  ·  Adrian VS Hill, MA, BM BCh, DPhil, DM (3)

Results publications

PMID 39787798, PMID 26383952, PMID 29217375, PMID 40245769, PMID 41014333, PMID 23526949, PMID 23899517, PMID 25211344, PMID 25801652, PMID 26292027, PMID 26292257, PMID 26424605, PMID 26458804, PMID 27695088, PMID 29389671, PMID 31932368, PMID 32239164, PMID 32275867, PMID 32394880, PMID 32572470, PMID 33717176, PMID 34194041, PMID 34265407, PMID 36682364, PMID 37971871, PMID 39324693, PMID 39708824, PMID 39805302, PMID 41176969, PMID 42253092, PMID 10190913, PMID 10501745, PMID 12663340, PMID 12742586, PMID 1313024, PMID 15069048, PMID 16904798, PMID 17075340, PMID 17428147, PMID 17940609, PMID 18190252, PMID 18213374, PMID 18231580, PMID 18253503, PMID 18270560, PMID 18337339, PMID 18378716, PMID 18545693, PMID 18612426, PMID 18698359

NIH funding

2019 (4), 2016 (3), 2015 (2), 2018 (2), U01CI000211 (2), 2014 (1), 2023 (1), 5UM1AI148373-03 (1), 5UM1AI148684-04 (1), N01AI085346 (1), R01AI025136 (1), R01HL086488 (1), R01NS074409 (1), U01AI065683 (1), U01AI066050 (1)